Inovio Plans Fresh Equity Raise Days After First FDA Approval
INO has more than doubled off its 52-week low of $0.563.
Summary
Inovio is going back to the equity market with an underwritten common stock offering, with Jefferies and Piper Sandler acting as joint book-running managers, and it is not disclosing the size or price yet. Underwriters get a 30-day option for up to 15% of the offered shares, so the final dilution could be larger than the base deal. The timing is the story: this comes days after the FDA granted accelerated approval to VOCERYQ (INO-3107) on October 30, and after an $80.4M court judgment against VGXI and GeneOne on October 20. The company entered Q2 with a going concern warning and cash runway only into late Q1 2027, so a raise was expected — but selling stock into the post-approval pop transfers the upside to new buyers at the expense of existing holders. The preliminary prospectus supplement will set the share count and price; that filing is where the real dilution math shows up.
At the time of this announcement, INO was trading at $1.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $149.9M. The 52-week trading range was $0.56 to $2.72. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.